Treatment of Behçet disease with oral roflumilast, an observational study.

Autor:	Peñuelas Leal R; Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain., Labrandero Hoyos C; Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain., Peñuelas Ruiz JA; Gandia Public Health Centre, Gandía, Spain., Bagán Debón LM; Clínica odontológica de Medicina Buccal, Valencia, Spain.; Oral Medicine department, University of Valencia. Valencia, Spain., Zaragoza Ninet V; Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain., Carazo JLS; Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain., Pérez Pastor G; Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain., Grau Echevarría A; Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain., Esteve Martínez A; Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain., Finello M; Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain., Blaya Imbernon D; Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain., Dios Guillán V; Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain., Aguilar González L; Hospital Puerta del Mar, Cádiz, Spain., Bagán Sebastián JV; Oral Medicine department, University of Valencia. Valencia, Spain.; Department of Oral and Maxillofacial Surgery, Consorci Hospital General Universitari de Valencia. Valencia, Spain., Alegre De Miquel V; Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain.; Dermatology Department, University of Valencia. Valencia, Spain.
Jazyk:	angličtina
Zdroj:	Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Jul 24. Date of Electronic Publication: 2024 Jul 24.
DOI:	10.1093/ced/llae284
Abstrakt:	Introduction: Mucocutaneous Behcet's disease is often a therapeutic challenge. Roflumilast has shown promise in other inflammatory dermatological conditions. The objective of this study is to evaluate the characteristics, effectiveness and safety of roflumilast in the treatment of Behçet's Disease-associated aphthosis in routine clinical practice. Methods: Single cohort ambispective observational study. 11 patients with Behçet disease treated with roflumilast participated. Data collection included demographic, clinical and outcome variables. Statistical analysis compared 12 weeks of treatment with roflumilast with a previous period without treatment and with a period with the previous treatment. Results: During treatment with roflumilast, a reduction in flare-ups and oral ulcers was observed compared to the untreated period and the previous treatment period. A reduction in genital ulcers, pain and ulcer duration was observed between the Whitout treatment period and the Roflumilast treatment period.Adverse effects occurred in 54% of patients, most of which were self-limiting or manageable with dose adjustment. No patient withdrew treatment. Discussion: Roflumilast appears a promising option in the treatment of Behçet's disease with favourable effectiveness, safety and tolerability profiles. Although further research is needed, roflumilast offers a promising treatment option for Behçet's Disease-associated aphthosis, which could improve patients' quality of life and address unmet therapeutic needs. (© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu